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Activator of G protein signaling 3 (AGS3) is a newly identified
protein shown to act at the level of the G protein itself. AGS3
belongs to the GoLoco family of proteins, sharing the 19-aa GoLoco
motif that is a Gai/o binding motif. AGS3 interacts only with
members of the Gai/o subfamily. By surface plasmon resonance, we
found that AGS3 binds exclusively to the GDP-bound form of Gai3.
In GTPgS binding assays, AGS3 behaves as a guanine dissociation
inhibitor (GDI), inhibiting the rate of exchange of GDP for GTP by
Gai3. AGS3 interacts with both Gai3 and Gao subunits, but has GDI
activity only on Gai3, not on Gao. The fourth GoLoco motif of AGS3
is a major contributor to this activity. AGS3 stabilizes Gai3 in its
GDP-bound form, as it inhibits the increase in tryptophan fluores-
cence of the Gai3-GDP subunit stimulated by AlF4
2. AGS3 is widely
expressed as it is detected by immunoblotting in brain, testis, liver,
kidney, heart, pancreas, and in PC-12 cells. Several different sizes
of the protein are detected. By Northern blotting, AGS3 shows
2.3-kb and 3.5-kb mRNAs in heart and brain, respectively, suggest-
ing tissue-specific alternative splicing. Taken together, our results
demonstrate that AGS3 is a GDI. To the best of our knowledge,
no other GDI has been described for heterotrimeric G proteins.
Inhibition of the Ga subunit and stimulation of heterotrimeric G
protein signaling, presumably by stimulating Gbg, extend the
possibilities for modulating signal transduction through heterotri-
meric G proteins.
Heterotrimeric G proteins (G proteins), consisting of an asubunit (Ga) with GTPase activity and a bg dimer (Gbg),
act as guanine nucleotide-dependent molecular switches in
signaling pathways that connect transmembrane receptors with
downstream effectors (1, 2). In the classical paradigm at the
plasma membrane, the liganded transmembrane receptor acti-
vates the G protein by stimulation of GDP dissociation from Ga
and acts as a guanine exchange factor (GEF), thereby enhancing
GTP binding and releasing free Ga and Gbg subunits to interact
with their respective effectors (3). Inactivation of G protein
signaling takes place by inhibiting G protein activation or by
GTP hydrolysis, which leads to reformation of the heterotrimer.
Precisely timed activation and inactivation of the G protein,
dependent on regulatory factors, is crucial in signal transduction.
In the case of the small G proteins, two classes of intracellular
proteins can act as inhibitors of G protein activation: GTPase
activating proteins (GAPs), which enhance GTP hydrolysis, and
guanine dissociation inhibitors (GDIs), which inhibit GDP dis-
sociation (4). GAPs for heterotrimeric G protein a subunits have
only recently been discovered and for the most part belong to the
RGS (regulator of G protein signaling) protein family (5–7).
Until now, GDIs acting on heterotrimeric G proteins have
remained elusive. However, several additional Ga-interacting
proteins, most of them displaying regulatory- or effector-like
functions, have recently been identified. PCP2 and activator of
G protein signaling (AGS) 1 are novel GEFs (8, 9) and
Rap1GAP is a novel effector (10, 11). AGS3, identified in a
functional screen based on G protein signaling in yeast but
unrelated to AGS1, was recently shown to bind to Gai-GDP and
act as an activator of heterotrimeric G protein signaling (12),
possibly through effectors of Gbg. In contrast to G protein
coupled receptors (the classical G protein activators), AGS3 did
not enhance GTPgS binding to the Ga subunit. Thus, it appar-
ently acts through a different, yet to be elucidated, molecular
mechanism (12). Here, we have further characterized AGS3 and
have demonstrated that it acts as a GDI for Gai3.
Materials and Methods
Isolation of AGS3 cDNA. For two-hybrid interaction screening, 50
mg of a rat GC cell (pituitary) cDNA library in pACT2 was
transformed into yeast HF7c(pGBT9Gai3) as described (13).
Twenty-four positive clones, grouped based on insert size and
restriction pattern, were sequenced from the 59 or 39 end by
automated sequencing. One of these was a partial clone for
AGS3, encoding the C-terminal half of the molecule (amino
acids 361–590), truncated by its last 60 aa. Full length AGS3 (650
aa) cDNA was obtained by reverse transcription (RT)-PCR on
rat brain cDNA (kind gift of Dr. E. Masliah, Department of
Pathology, University of California at San Diego), based on the
reported sequence (GenBank no. AF107723).
Online BLAST searches were performed via the website of the
National Center for Biotechnology Information (NCBI), Be-
thesda, MD (14). PROSITE was used for searching motifs, and
protein structure analysis (PSA) (BMERC, Boston, MA) was
used for secondary structure analysis.
Northern Blot Analysis. A multiple tissue blot of poly(A)1 RNA
from rat tissues (CLONTECH) was hybridized to a 200-bp
cDNA fragment (corresponding to AGS3591–650 cDNA). The
probe was labeled by random priming with [32P]dCTP (3000
Ciymmol) (Amersham). Quickhyb solution (Stratagene) was
used under high-stringency conditions for hybridization (68°C),
and high-stringency washes were performed in 0.13 SSC [150
mM NaCly15 mM sodium citrate (pH 7)] plus 0.1% SDS, at
60°C. Autoradiographs were exposed for 3 days at 270°C with
intensifying screens.
Antibody Production. Anti-AGS3 antibody was raised in rabbits
(Covance, Richmond, CA) against the last 14 aa (KGPD-
PRQQSPPGAS) at the C terminus of AGS3, which has no
homologies to other known mammalian proteins. IgG was
affinity purified on the same peptide coupled to Affigel 10
(Bio-Rad). The affinity-purified IgG (8.5 mgyml) recognized 1
ng purified recombinant AGS3 protein by immunoblotting.
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Immunoblotting Analysis. A rat multiple tissue Western blot (Gene
Technology, St. Louis, MO) containing lysates (75 mg) of each
of nine different tissues (prepared in the presence of protease
inhibitors) or immunoblots prepared from PC-12 cells were
incubated in TBS [10 mM Tris (pH 7.5)y100 mM NaCly5 mM
KCl] supplemented with 0.1% Tween 20, 5% FCS, and 8.5
mgyml affinity-purified anti-AGS3 IgG. Detection was per-
formed by enhanced chemiluminescence (ECL) using Supersig-
nal West Pico substrate (Pierce).
Preparation of Cell Fractions. PC-12 cells were maintained in
DMEM (high glucose) medium supplemented with 10% horse
serum and 5% FBS. Postnuclear supernatants were prepared
and separated into particulate and cytosolic fractions by cen-
trifugation (100,000 3 g for 1 h) as described (15). Fractions
(normalized by volume) were loaded on 10% SDSyPAGE gels
for protein separation, transferred onto poly(vinylidene difluo-
ride) (PVDF) membranes, and immunoblotted with affinity-
purified anti-AGS3 antibody, and detection was performed
by ECL.
Two Hybrid Interactions. AGS3361–590 or AGS3361–650 in pACT2
vector were cotransformed in yeast strain SFY526 (CLON-
TECH) with the following Ga subunits subcloned into pGBT9
vector: rat Gai3 (16), rat Gai2, mouse Ga12, and mouse Gaq from
P. Insel (University of California at San Diego), rat Gai1 from
T. Kosasa (University of Texas, Southwestern Medical Center),
rat Gas from H. Bourne (University of California at San
Francisco), rat Gao1 from E. Neer (Brigham and Women’s
Hospital, Boston), rat Gaz from E. Ross (University of Texas,
Southwestern Medical Center), and Saccharomyces cerevisiae
GPA1 from J. Noel (Salk Institute). Interactions were analyzed
qualitatively by a colony lift assay for b-gal using 5-bromo-4-
chloro-3-indolyl b-D-galactoside (17), and the appearance of
blue colonies was assessed (2 to 111) after 2, 4, and 8 h. No
background color was detected after 20 h.
Preparation of Recombinant Fusion Proteins. A cDNA fragment
coding for AGS3424–650 was cloned into pGEX-KG vector (Phar-
macia) and expressed in Escherichia coli DH5a. The protein was
purified according to the manufacturer’s instructions and used
for surface plasmon resonance (BIAcore) assays (see below).
AGS3424–650 and AGS3591–650 cDNAs were subcloned into
pET28a vector (Novagen), and hexahistidine (His) fusion pro-
teins were expressed in E. coli BL21(DE3) strain. Bacteria were
induced at room temperature with 0.4 mM isopropyl b-D-
thiogalactoside (IPTG). Bacterial pellets were resuspended in
lysis buffer [1% Tween 20y25 mM Tris (pH 8)y500 mM NaCly5
mM imidazole] supplemented with 200 mgyml lysozyme. His-
AGS3 proteins were purified by affinity chromatography on
Ni21-NTA resin (Qiagen, Chatsworth, CA) and eluted with lysis
buffer containing 250 mM imidazole. His-Gai3, His-Gao1, and
His-Gas subunits were purified as described (18). Concentra-
tions of recombinant proteins were estimated by SDSyPAGE
after Coomassie staining with known amounts of BSA as stan-
dards. Purified His-AGS3 proteins were dialyzed overnight in 10
mM Hepes (pH 7.5), 1 mM DTT, and 0.05% polyoxyethylene 10
lauryl ether (C12E10, Sigma). Aliquots were kept frozen at
280°C until used for in vitro interactions or GTPgS binding
assays.
In Vitro Interactions by Surface Plasmon Resonance. Binding mea-
surements were performed on a BIAcore 2000 (Biacore, Pisca-
taway, NJ) at the University of North Carolina, Chapel Hill
Macromolecular Interactions Facility. Goat anti-GST IgG (af-
finity purified, Biacore) was coupled (1 mg per coupling) to
separate carboxymethylated, dextran-coated sensor surfaces
(Sensor Chip CM5) that had been activated by using N-
hydroxysuccinimide (NHS) and N-ethyl-N9-(dimethylaminopro-
pyl)carbodiimide (EDC) according to the manufacturer’s in-
structions. Antibody coupling was followed by injection of 1 M
ethanolamine hydrochloride to inactivate the remaining NHS
groups. Recombinant GST and GST-AGS3424–650 were bound to
the anti-GST IgG and gave 4400 and 6500 response units (RU),
respectively.
Binding analyses were performed at 25°C in HBS-PyM run-
ning buffer [10 mM Hepes (pH 7.4)y150 mM NaCly16 mM
MgCl2y0.005% (volyvol) Nonidet P-40]. Myristoylated, recom-
binant rat Gai3 protein (purchased from Calbiochem) was
diluted to 0.8 mM in HBS-PyM buffer containing either 32 mM
GDP, 32 mM GDP plus 32 mM AlCl3 and 10 mM NaF, or 32 mM
GTPgS. Gai3 protein aliquots containing GDP or GDP plus
AlF4
2 were incubated for 30 min at 30°C before injection. The
Gai3 protein aliquot containing GTPgS was preincubated over-
night at room temperature to allow binding of GTPgS. Each
preincubated Gai3 sample with corresponding guanine nucleo-
tide dilution buffer (25 ml) was injected into three different
channels of both the GST-AGS3 and GST chips at a flow rate
of 5 mlymin. Background binding to the GST surface was
subtracted from binding curves of the GST-AGS3 surface by
using BIAevaluation software version 3.0 (Biacore). Surface
regeneration was performed by 10-ml injections of 1 M NaCl in
10 mM NaOH at a 30 mlymin flow rate.
GTPgS Binding Assay. GTPgS binding experiments were per-
formed with 2 mM [35S]GTPgS (1000 Ciymmol; 2000
cpmypmol) and 1 mM His-AGS3424–650 or His-AGS3591–650
proteins in binding buffer [50 mM Tris (pH 8.0)y1 mM DTTy1
mM EDTAy10 mM MgSO4). Reactions (50 ml) were started by
addition of His-Gai3-GDP, His-Gao-GDP, or His-Gas-GDP (2.5
pmolsyassay), incubated at 30°C and terminated by rapid filtra-
tion through nitrocellulose filters followed by washing with ice
cold binding buffer (3 times; 4 ml). Bound radioactivity was
determined by scintillation counting. Specific binding was ,5%
of the total radioactivity, and GTPgS binding to AGS3 was ,2%
of the binding to the Ga subunits.
Spectrofluorometric Analysis of the AGS3yGai3 Interaction. The
increase in intensity of fluorescence of the tryptophan residues
in Ga is an indicator for its structural change from the inactive
to the active state (19–21) and can be monitored by spectroflu-
orometry. Fluorescence measurements were performed with a
Shimadzu RF 5000 fluorometer with excitation at 292 nm and
emission at 342 nm (bandwidths 5 and 30 nm, respectively). For
activation of Ga, 300 nM His-Gai3-GDP in 20 mM TriszHCl, 120
mM KCl, 2 mM MgCl2, 1 mM DTT, 20 mM GDP, was equili-
brated at 25°C in the cuvette, and NaF (2 mM) and AlCl3 (30
mM) (final concentrations) were added after 10 and 11 min,
respectively. To determine the effect of AGS3 on Ga activation
by AlF4
2, a complex of 300 nM GST-AGS3424–650 and 300 nM
Gai3-GDP was preformed (15 min at 25°C) in the same buffer
and then activated as described above. AGS3424–650 itself con-
tains no tryptophan residues. The signal generated from the GST
moiety of GST-AGS3424–650 (which contains 4 tryptophans) was
deducted from the total signal.
Results
AGS3 Belongs to a Family of Proteins with Conserved Motifs. To
search for proteins that can interact with Gai3, we screened a
yeast two-hybrid library from rat GC (pituitary) cells as previ-
ously described (13). One of the positive clones coded for
residues 361 to 590 of the AGS3 protein (Fig. 1A), whose
full-length, 650-aa sequence was recently described by Takesono
et al. (12). Other positive clones coded for GAIP (16), Calnuc
(nucleobindin) (13), and LGN (22).
The C-terminal half of AGS3 shows homologies to the fol-








lowing proteins: LGN (22), PCP2 (8), RGS12, RGS14 (23),
Rap1GAP (11), Loco (24), and partner of inscuteable (PINS)
(25, 26). All of these proteins have in common one or several
19-aa GoLoco motifs (Fig. 1B) (27), which have also been called
GPR motifs (12). The GoLoco motif is repeated four times in
AGS3 and LGN and three times in PINS. Each of the four
GoLoco motifs of AGS3 corresponds to a predicted a-helix. The
N-terminal half of AGS3 contains 7 tetratricopeptide (TPR, 34
aa) motifs (Fig. 1 A) that in other proteins have been implicated
in protein–protein interactions (28). Seven TPR motifs are also
present in LGN and in PINS. Each TPR motif also corresponds
to a predicted a-helix. Because the C-terminal half of AGS3
interacts with Ga, we have restricted our study to this region of
the molecule in subsequent assays.
AGS3 Is Expressed in Multiple Tissues. When a fragment coding for
the C-terminus (amino acids 591–650) of rat AGS3 cDNA was
used as a probe in a rat tissue Northern blot, mRNAs of 2.3 kb
and 3.5 kb were detected in heart and brain, respectively (Fig.
2A). No detectable mRNAs were found in other tissues with this
probe, probably because of the limited sensitivity of the North-
ern blotting technique or to mRNA instability.
To determine the sites of expression of the AGS3 protein, we
performed Western blotting with an affinity-purified AGS3-
specific antibody (directed to the C terminus of AGS3) on a
multiple rat tissue Western blot. Immunodetection revealed the
presence of single bands with different sizes in several tissues.
We detected a 75-kDa protein corresponding to the deduced
full-length AGS3 protein described by Takesono et al. (12) in
brain and testis (Fig. 2B) and specific bands of smaller size in
liver (53 kDa), kidney (42 kDa), heart (26 kDa), and pancreas
(35 kDa). No bands were detected in lung, spleen, and ovary
under these conditions. Brain and liver lysates showed the
highest immunoreactivity, and heart and pancreas the lowest. By
RT-PCR (primers in the region coding for amino acids 424 to 430
and 645 to 650), we detected a transcript in kidney (data not
shown). We also identified a rat expressed sequence tag (EST)
sequence (GenBank no. C06699) from pancreas and a human
EST sequence (different splice form) from an oligodendrogli-
oma (GenBank no. AI272212) by BLAST homology searches
(GenBank).
Our Western blot and RT-PCR data together with the EST
data indicate that expression of AGS3 is more widespread than
anticipated by mRNA expression levels on Northern blots and
suggest that there may be alternatively spliced forms of AGS3 in
different tissues.
Distribution of AGS3 in Cell Fractions. As a first approach to
determine the cellular localization of AGS3, we surveyed its
expression in several cell lines (AtT-20 and GC pituitary cell
lines, HEK-293, MDCK, PC-12, and REF52 cells). Because
nondifferentiated PC-12 cells showed the highest levels of
expression of the 75-kDa form, we determined the distribution
of AGS3 by immunoblotting in cytosolic (100,000 3 g superna-
tant) and particulate (100,000 3 g pellet) fractions from these
cells. The majority (95%) of the protein was found in the
cytosolic fraction (Fig. 3), but 5% sedimented with the partic-
ulate fraction, indicating its association with membranes or
cytoskeletal elements. We therefore conclude that the 75-kDa
form of AGS3 is mainly a cytosolic protein in nondifferentiated
PC-12 cells.
AGS3 Interacts with Gai/o Subunits. To determine the specificity of
AGS3 for different Ga subunits, we used the two-hybrid system.
Results of the qualitative filter lift assay (Table 1) showed that
AGS3 interacts with Gai1, Gai2, Gai3, and Gao, but no interac-
tion was detected with Gaz, Gas, Gaq, or Ga12 in this assay.
Interaction with Gao and Gai2 was slightly weaker than with Gai1
and Gai3. Interestingly, AGS3 did not interact with Gpa1, the
yeast Ga subunit that is most similar to the mammalian Gai
subfamily (29). For unknown reasons, AGS3361–590, the trun-
cated form we originally isolated, showed a stronger interaction
with Gai3 than AGS3361–650.
AGS3 Interacts with the GDP-Bound Form of Gai3. We investigated
the nucleotide dependence of the binding of recombinant Gai3
to AGS3 by surface plasmon resonance (BIAcore) analysis.
GST-AGS3424–650 and GST control proteins were immobilized
with anti-GST IgG that had been covalently coupled to a
dextran-coated biosensor surface. Recombinant Gai3 was pre-
Fig. 1. Schematic representation of the AGS3 protein and alignment of
GoLoco motifs. (A) AGS3 (650 aa) contains 7 N-terminal tetratricopeptide
(TPR) motifs (T1 to T7) and 4 C-terminal GoLoco motifs (G1 to G4). Important
landmark amino acids for AGS3 constructs used in our experiments are shown
by arrows. AGS3361–590 is sufficient for interaction with Gai/o subunits. (B)
Alignment showing 15 GoLoco motifs (19 aa) from 7 proteins with identical
residues, boxed and conserved substitutions shown in bold. The consensus
sequence was defined by the amino acid most represented in each position.
Fig. 2. (A) Expression of AGS3 mRNA. Analysis of a rat multiple tissue
Northern blot with an AGS3 probe shows a 2.3-kb mRNA in heart (lane 1) and
a 3.5-kb mRNA in brain (lane 2). No mRNAs were detected in spleen (lane 3),
liver (lane 4), lung (lane 5), skeletal muscle (lane 6), kidney (lane 7), or testis
(lane 8) under these conditions. (B) Expression of AGS3 protein. Analysis of a
rat multiple tissue Western blot (75 mg proteinylane) with affinity-purified
AGS3 IgG (8.5 mgyml in TBS, 0.1% Tween 20, 5% FCS) showing that AGS3
protein is widely expressed. A 75-kDa protein is detected in brain (lane 2) and
testis (lane 6). Liver (lane 1), kidney (lane 4), heart (lane 8), and pancreas (lane
9) showed a single protein band at 53, 42, 26, and 35 kDa, respectively. No
AGS3 immunoreactivity was detected in lung (lane 3), spleen (lane 5), and
ovary (lane 7) under these conditions.
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incubated with GDP, GDP 1 AlF4
2, or GTPgS and passed over
these surfaces. In this assay, AGS3 clearly interacted exclusively
with the inactive (GDP-bound) form of Gai3 (Fig. 4), suggesting
it could be either a GEF or a GDI.
AGS3 is a GDI. To determine whether AGS3 functions as a GEF
or a GDI, we performed GTPgS (a nonhydrolyzable analog of
GTP) binding experiments. Increased GTPgS binding to Gai3
would imply AGS3 is a GEF, whereas decreased binding would
imply that AGS3 is a GDI. Addition of 1 mM AGS3424–650
decreased the binding of GTPgS to 0.05 mM Gai3 by 5 min, and
after 80 min incubation binding was reduced by 85% (Fig. 5). By
contrast, no inhibitory effect on GTPgS binding to Gao and Gas
(Fig. 5) was found in the presence of AGS3424–650. Based on this
assay, we conclude that AGS3 is a specific GDI for Gai3. This
specificity toward Gai3 is surprising because AGS3 interacts with
Gao, a member of the Gai subfamily, in the two-hybrid assay.
Further analysis showed that AGS3591–650 (the last 60 aa of
AGS3), containing GoLoco 4 also significantly reduced GTPgS
binding to Gai3 ('75%) (Table 2). We conclude that the
C-terminal half of AGS3 containing the GoLoco motifs is
responsible for the GDI effect on Gai3 and that the fourth
GoLoco motif in particular is the major contributor to this effect.
However, further studies are needed to determine the impor-
tance of each separate GoLoco domain.
AGS3 Inhibits the Activation of Gai3 by AlF4
2. To confirm the
inhibitory effect of AGS3 on Gai3 activation, we determined the
effect of AGS3 on the activation of Gai3-GDP by analyzing the
intrinsic tryptophan fluorescence of the Ga subunit in the
presence or absence of AlF4
2. It has been shown that the intensity
of tryptophan fluorescence increases significantly on activation
of Gai3-GDP by AlF4
2 (19–21) as a consequence of the confor-
mational change of the Ga subunit. The binding of AGS3424–650
to Gai3-GDP significantly inhibited Ga activation by AlF4
2 (Fig.
6). The fluorescence signal for Gai3 never reached the level of
the AlF4
2-activated Gai3 in presence of AGS3424–650, even after
longer measurements (15 min, data not shown). These results
indicate that AGS3 inhibits the conformational change in Gai3
Fig. 3. Distribution of AGS3 protein in membrane and cytosolic fractions of
PC-12 cells. A postnuclear supernatant (PNS) was centrifuged at 100,000 3 g
to yield particulate (P) and cytosolic (C) fractions. These fractions (normalized
by volume) were immunoblotted with affinity-purified AGS3 IgG and de-
tected by ECL, and the amount found in each fraction was quantified by
densitometry. The majority of AGS3 (.95%) is found in the cytosolic fraction,
but a small amount (5%) is found in the particulate fraction.
Fig. 4. In vitro interactions of AGS3 with Gai3 assessed by surface plasmon
resonance. AGS3 interacts with Gai3-GDP but not with Gai3-GTPgS or Gai3-
GDP-AlF4
2. GST-AGS3424–650 fusion protein or GST protein were bound to
anti-GST IgG covalently coupled to separate Biacore chips. Gai3 was preincu-
bated with GDP, AlF4
2, or GTPgS as described in Materials and Methods and
then injected in the flow buffer (simultaneous coinjection over both chips)
into a BIAcore 2000. The signal generated by GST alone was deducted from the
GST-AGS3424–650 signal.
Fig. 5. AGS3 is a GDI for Gai3. Shown is the time course of GTPg35S binding
by Gai3-, Gao-, and Gas-GDP in the absence or presence of AGS3424–650. AGS3
inhibits (up to 85%) GTPgS binding to Gai3. The effect is observed as early as
5 min and lasts over the entire 80-min time period. No inhibition of GTPgS
binding to Gao or Gas is observed in the presence of AGS3424–650. GTPg35S was
incubated in the absence or presence of 1 mM His-AGS3424–650. Ga-GDP (50 nM
final) subunits were added to start the reaction, and the reaction was stopped
at different times by filtration. Results represent the mean of three (Gas, Gao)
or four (Gai3) experiments.












The b-gal filter assay was performed on (Leu2, Trp2) plates, and intensity of
color was scored after 8 h. 2, no color; 11, moderate color; 111, strong
color; 1111, very strong color. Yeast cotransformed with void bait and prey
vectors were taken as background (none detected after 20 h). Baits were
constructed in pGBT9, and AGS3 preys were in pACT2. Three independent
experiments were performed with the same results.








from the inactivated to the activated state by stabilizing it in its
GDP-bound form. These findings also define AGS3 as a GDI.
Discussion
AGS3 was recently isolated and characterized by Takesono and
coworkers as a receptor-independent activator of G protein
signaling through a functional screen in yeast and was shown to
preferentially bind to the GDP-bound form of Gai2 and Gai3 in
GST pulldown assays (12). This suggested that AGS3 might act
as either a GEF or a GDI, stimulating or inhibiting, respectively,
the exchange of GDP for GTP. Because these workers found no
change in GTPgS binding to Gai2 and to trimeric G proteins
purified from brain (mainly Gao) in the presence of AGS3, they
were not able to conclude whether AGS3 is a GEF or a GDI (12).
We confirmed AGS3’s specific interaction with the GDP-bound
form by surface plasmon resonance (BIAcore) where AGS3
binds exclusively to Gai3-GDP. In addition, we demonstrated
that AGS3 behaves as a GDI by showing that GTPgS binding by
Gai3 was decreased 6-fold in the presence of AGS3424–650.
AGS3591–650, containing only GoLoco 4 (14 aa shorter than the
protein used by Takesono et al. (12)), also showed potent GDI
activity in this assay. We confirmed that AGS3 behaves as a GDI
by using spectrofluorometry, a classical technique that measures
the increase in fluorescence of Ga tryptophan residues after the
switch from the inactive (GDP-bound) state to the active
(GTP-bound) state. Preincubation of Gai3 with AGS3424–650
significantly inhibited the activation of Gai3 by AlF4
2, indicating
that it stabilizes Gai3 in its GDP-bound state.
Takesono et al. suggested that AGS3 and Gbg can compete for
binding to the Ga-GDP subunit (12), and we have found in this
work that AGS3 is a GDI that keeps the Ga subunit in its inactive
state. These observations suggest that the AGS3yGai3 interac-
tion might prevent Gbg from returning to Ga and thus leads to
enhanced Gbg-dependent signaling, which corresponds to what
Takesono et al. (12) observed when isolating AGS3 in their
functional screen in yeast, as the signaling pathway leading to
proliferation and survival in yeast depends on Gbg signaling.
AGS3 would thus selectively shut off signaling pathways linked
to Ga effectors and favor Gbg effector pathways.
It is interesting to note that AGS3 could still activate G protein
signaling through a G204A mutant (mimicking the GDP-bound
form) of Gai2 (12), which is incapable of releasing Gbg after
activation by a receptor (30). These findings suggest that AGS3
activates G protein signaling via a different mechanism than a
receptor does.
An as yet unknown intracellular regulatory mechanism must
be invoked for AGS3 to act on Ga, maybe by translocation or by
interaction with other signaling partners. The GDIs for small G
proteins generally prevent translocation of the small G protein
to their membrane-bound activators (GEFs) by keeping the
GDIysmall G protein complex in the cytosol (4). A similar
mechanism might take place in the case of AGS3, preventing Gai
activation by keeping Ga in the GDP-bound state and by keeping
Ga away from membranes.
The results of our two-hybrid interaction assay with a panel of
Ga subunits demonstrates that AGS3 binds to all members of the
Gai/o subfamily with the exception of Gaz, but does not bind to
Gas, Gaq, or Ga12. Data from GTPgS binding assays show that
AGS3 is a GDI for Gai3, but surprisingly not for Gao. Thus,
AGS3 is capable of binding to Gao, but its GDI activity seems
restricted to Gai3, although we have not tested GDI activity of
AGS3 on Gai1 and Gai2. This specificity is also surprising
because AGS3 and Gao are both highly expressed in brain.
Additional research is needed to address the in vivo specificity
of AGS3.
BLAST searches with AGS3 showed strong local homologies to
the following mammalian proteins: LGN (22), PCP2 (8), RGS12
and RGS14 (23), Rap1GAP (11), Loco (24), and PINS (25, 26).
The common sequence in these proteins is restricted to a 19-aa
motif, recently named GoLoco (27) or GPR (12), which defines
a newly recognized family of proteins. AGS3 and LGN contain
four GoLoco motifs, PINS contains three and PCP2, RGS12,
RGS14, Rap1GAP, and Loco only one. All these proteins have
in common the ability to bind to Gai/o subunits (27). The fact that
both PCP2 and Rap1GAP, each with only one GoLoco repeat,
were isolated in two-hybrid screens with Gao indicates that the
presence of one such motif is sufficient for interaction with Ga.
The single GoLoco motifs of RGS12 and RGS14 (RGS domains
deleted) were also found to be sufficient for binding to Gai
subunits (R. Kimple and D.P.S., unpublished data).
At this time, the role of each GoLoco motif in AGS3 is not
clear. The AGS3 cDNA fragment we originally isolated based on
its ability to bind Gai3 coded for only the first 3 GoLoco motifs,
suggesting that the 4th (C-terminal) GoLoco motif is not essen-
tial for the interaction with Gai3. However, we found GoLoco 4
to be an important component for the GDI activity of AGS3.
GoLoco motifs functionally act as general binding motifs
to Gai/o subunits. However, the structural requirements for
nucleotide-specific binding (to GDP- or GTP-bound Ga) and for
specific interactions within the Gai/o subfamily have not been
Table 2. The C-terminus of AGS3 inhibits GTPgS binding to Gai3
Time, min
GTPgS bound, % of total binding
— 1AGS3424–650 1AGS3591–650
10 100 16.6 28.9
80 100 15.7 26.2
GTPgS was incubated in the absence or presence of 1 mM each of His-
AGS3424–650 or His-AGS3591–650. Reactions were started by addition of 10 ml of
Gai3-GDP (250 nM). Results represent the percentage of GTPgS binding re-
maining after 10 and 80 min of incubation. Binding of Gai3, defined as 100%,
was 0.27 6 0.01 after 10 min and 1.15 6 0.04 pmol after 80 min. AGS3424–650
(4 GoLocos) and AGS3591–650 (last GoLoco) inhibit (84% and 74%, respectively)
the binding of GTPgS to Gai3. n 5 3.
Fig. 6. AGS3 stabilizes Gai3 in its inactive GDP-bound form. Activation of Gai3
by AlF4
2 is visualized by a dramatic enhancement of the fluorescence of Gai3
tryptophans. The amplitude of activation of Gai3 is significantly decreased in
the presence of AGS3424–650. Gai3-GDP was preincubated in the absence or
presence of AGS3424–650 before addition of NaF (arrow 1) and AlCl3 (arrow 2).
Tryptophan fluorescence was monitored by spectrofluorometry as described
in Materials and Methods. Time is expressed in seconds and fluorescence in
arbitrary units.
14368 u www.pnas.org De Vries et al.
extensively addressed. Most GoLoco proteins that have been
studied interact with the GDP-bound forms of Gai/o subunits.
LGN, the closest homolog of AGS3, preferentially interacted
with the GDP-bound form of Gai2 (22), and PCP2 preferentially
interacted with the GDP-bound form of Gao. The nucleotide
preference of Rap1GAP is unclear as one report indicates it
interacts with the GDP-bound form of Gao (10) and another
with the GTP-bound form of Gai1 and Gai2 (11). A third study
reported interaction of Rap1GAP with GTP-bound Gaz and
Gai2, but not with GTP-bound Gao (31). Preferential binding of
a protein to GDP-bound Ga subunits indicates that it functions
either as a GEF or as a GDI. Based on the ability of PCP2 to
stimulate GDP release from Gao, it was suggested that proteins
with GoLoco domains are GEFs for Gai/o subunits (8, 27).
However, here we show that the GoLoco motifs of AGS3, all
four together as well as the C-terminal GoLoco alone, behave as
a GDI. Thus, specific residues within or the structural context
surrounding each GoLoco motif might dictate whether the
protein behaves as a GEF or a GDI, respectively. Mutational
analysis of GoLoco motifs and their amino acid context should
shed light on these issues.
Although we have attributed a GDI function to the GoLoco
motifs of AGS3, no role yet has been found for its N-terminal
TPR motifs. TPR motifs are found in a variety of functionally
unrelated molecules and have been implicated in protein–
protein interactions (28). PINS was originally isolated by inter-
action of its N-terminal 7 TPR motifs with the Drosophila
Inscuteable protein (25). The third TPR motif in p67phox, a
subunit of the NADPH oxidase complex that has four TPRs,
has been implicated in the binding of GTP-bound Rac, a small
GTPase (32). These results raise the possibility that AGS3 might
function as a connector molecule that links GDP-Gai/o (via its
GoLoco motifs) to other signaling pathways via its TPR motifs.
It is our goal to identify proteins that interact with the N-
terminal TPR domains of AGS3 as they may reveal additional
clues to AGS3’s function, its exact moment of action, and its
effects on G protein signaling.
We have found that AGS3 is widely expressed, but different
isoforms may be expressed in different tissues. Using a specific
affinity-purified anti-peptide antibody directed against the ex-
treme C terminus of AGS3, we detected several forms of AGS3
by immunoblotting. Each organ showed only one immunoreac-
tive band, but their size varied. The 75-kDa form detected in
brain, testis, and PC-12 cells corresponds to the size of the AGS3
protein deduced from its cDNA isolated from rat brain (12).
Additional isoforms were detected in liver (53 kDa), kidney (42
kDa), heart (26 kDa), and pancreas (35 kDa). The existence of
alternative spliced forms of AGS3 is suggested by our Northern
blot analysis, showing two different sizes of mRNA for heart and
brain, and by the cDNA sequence of a human EST isolated from
an oligodendroglioma. Although AGS3 mRNA was detected
only in heart and brain by Northern blotting, RT-PCR per-
formed on kidney RNA showed the expression of an mRNA that
codes for AGS3. Furthermore we have isolated an AGS3 cDNA
from rat pituitary, and the existence of a rat EST from pancreatic
islets has been documented. The relationship between these
different mRNAs remains to be established; however, our
collective evidence suggests the existence of multiple isoforms of
AGS3 probably produced by alternative splicing. Further mo-
lecular characterization of the liver, kidney, heart, and pancreas
forms should clarify the significance of these different forms.
In summary, in this study we have described the molecular
mechanism whereby AGS3 acts on the Ga subunit and found
that it is a GDI. Crystallographic data of the AGS3yGa-GDP
complex will possibly refine the molecular details of this inter-
action, and localization of this complex within the cell may help
to define its function. It is already clear that, with the discovery
of AGS3 and its GDI activity, an interesting complexity has been
added to the classical G protein signaling paradigm.
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